Document Detail


Maintenance of adequate hemodialysis access. Prevention of neointimal hyperplasia.
MedLine Citation:
PMID:  8589464     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The maintenance of adequate hemodialysis vascular access is frequently complicated in the patient with polytetrafluoroethylene (PTFE) A-V hemodialysis grafts by venous anastomotic stenosis. This stenosis is caused by neointimal hyperplasia (NIH), a response to vascular injury. In this study, the authors prospectively analyzed the effect of a short-term regimen consisting of administration of two medications, heparin and low molecular weight dextran, on the development of NIH at the venous anastomosis in 79 patients with PTFE A-V hemodialysis grafts. In addition, they evaluated other parameters' effects on the development of NIH. In comparison with control subjects, heparin had some effect in minimizing the development of NIH in the PTFE grafts when evaluated radiologically at 3 months, although this effect was not statistically significant. Low molecular weight dextran, however, had no trend or statistically significant effect on this venous anastomotic narrowing. Interestingly, patient age, use of calcium channel blockers, and presence of diabetes mellitus (DM) all appeared to affect the development of NIH. Increasing age and use of calcium channel blockers was associated with decreased development of NIH; conversely, DM was associated with worsened NIH. In evaluation of access survival (time to first access failure), degree of venous anastomosis stenosis at 3 months was not predictive. Patient time on dialysis pre graft placement was the only measured parameter related to access failure. The method of dialysis pre graft placement (hemodialysis versus peritoneal dialysis) was not a significant factor in early access failure. Pharmacologic treatment of venous anastomotic narrowing in PTFE hemodialysis grafts due to NIH continues to be difficult. Short-term treatment with the tested medication failed to statistically affect NIH. Patient age, use of calcium channel blockers, and presence of DM were all factors in the development of NIH. Of measured parameters, time on dialysis pre graft placement was the only factor correlated with early access failure. In future treatment regimens, one should consider more prolonged treatment. In addition, noted risk factors should be considered when determining type of renal replacement therapy.
Authors:
T E Taber; P S Maikranz; B W Haag; G M Gaylord; R S Dilley; K O Ehrman; P B Brown; D R Nelson; D C Kay; T L Roberts
Related Documents :
19400884 - Randomized nonblinded comparison of convalescence for 2 and 7 days after split-thicknes...
16567244 - Posttransplantation quality of life: more than graft function.
7761514 - The antithrombotic effects of ticlopidine and aspirin in a microvascular thrombogenic m...
23284994 - Virologic, immunologic and clinical responses in foreign-born versus us-born hiv-1 infe...
7921394 - Treatment of endometriosis by carbon dioxide laser during gamete intrafallopian transfer.
8980864 - Treatment of multidrug-resistant tuberculosis in taiwan.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  ASAIO journal (American Society for Artificial Internal Organs : 1992)     Volume:  41     ISSN:  1058-2916     ISO Abbreviation:  ASAIO J.     Publication Date:    1995 Oct-Dec
Date Detail:
Created Date:  1996-03-27     Completed Date:  1996-03-27     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9204109     Medline TA:  ASAIO J     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  842-6     Citation Subset:  IM    
Affiliation:
Department of Nephrology, Methodist Hospital of Indiana, Community Hospitals of Indiana, Indianapolis, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aging / metabolism
Analysis of Variance
Anticoagulants / administration & dosage,  pharmacology,  therapeutic use*
Arteriovenous Anastomosis / physiopathology*
Calcium Channel Blockers / pharmacology
Catheters, Indwelling / adverse effects,  standards*
Constriction, Pathologic / etiology,  physiopathology,  prevention & control
Dextrans / administration & dosage,  pharmacology,  therapeutic use
Diabetes Mellitus / physiopathology
Endothelium, Vascular / drug effects,  injuries,  pathology*
Female
Fibrinolytic Agents / administration & dosage,  pharmacology,  therapeutic use*
Heparin / administration & dosage,  pharmacology,  therapeutic use
Humans
Hyperplasia / complications,  physiopathology,  prevention & control
Kidney Transplantation
Linear Models
Male
Middle Aged
Molecular Weight
Polytetrafluoroethylene / adverse effects
Renal Dialysis / adverse effects,  standards*
Risk Factors
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Calcium Channel Blockers; 0/Fibrinolytic Agents; 9002-84-0/Polytetrafluoroethylene; 9004-54-0/Dextrans; 9005-49-6/Heparin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Determination of native mixed venous saturation during venovenous extracorporeal circulation.
Next Document:  Failure of low molecular weight dextran to prevent clotting during continuous renal replacement ther...